Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

4.52
+0.10002.26%
Post-market: 4.520.00000.00%19:49 EDT
Volume:7.54M
Turnover:34.39M
Market Cap:977.12M
PE:-30.13
High:4.80
Open:4.40
Low:4.37
Close:4.42
52wk High:8.21
52wk Low:0.4000
Shares:216.18M
Float Shares:113.00M
Volume Ratio:1.14
T/O Rate:6.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1500
EPS(LYR):-0.1500
ROE:-35.25%
ROA:-8.99%
PB:9.87
PE(LYR):-30.13

Loading ...

NASD Most Active Issues

Dow Jones
·
Mar 17

BRIEF-CytomX Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
Mar 17

BRIEF-CytomX Therapeutics Inc Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing

Reuters
·
Mar 17

CytomX Therapeutics launches USD 250 million follow-on stock offering

Reuters
·
Mar 17

CytomX Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Mar 17

CytomX Therapeutics Inc - Commences $250 Mln Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Mar 17

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Mar 17

BUZZ-CytomX jumps on promising trial data for colorectal cancer drug

Reuters
·
Mar 17

Top Midday Gainers

MT Newswires Live
·
Mar 17

CytomX Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 17

CytomX Therapeutics Raised to Overweight From Neutral by JP Morgan

Dow Jones
·
Mar 16

CytomX Therapeutics upgraded to Overweight from Neutral at JPMorgan

TIPRANKS
·
Mar 16

CytomX Therapeutics Inc : JP Morgan Raises to Overweight From Neutral; Raises Target Price to $12 From $7

THOMSON REUTERS
·
Mar 16

Wedbush Adjusts Price Target on CytomX Therapeutics to $11 From $6, Maintains Outperform Rating

MT Newswires Live
·
Mar 16

Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Mar 16

CytomX Therapeutics price target raised to $12 from $10 at Oppenheimer

TIPRANKS
·
Mar 16

Sector Update: Health Care

MT Newswires Live
·
Mar 16

CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment

MT Newswires Live
·
Mar 16

BRIEF-Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer

Reuters
·
Mar 16

CytomX Therapeutics reports Q4 EPS (22c), consensus (9c)

TIPRANKS
·
Mar 16